Urteste Publishes First Peer-Reviewed Panuri Study

Urteste said July 22, 2026, that Diagnostics has published the first peer-reviewed paper on the analytical validation of Panuri, its urine-based pancreatic cancer test. The company said the milestone supports ongoing multicenter clinical work in Europe and comes ahead of a presentation at ADLM 2026 in Anaheim.

Why it matters: - The publication gives Urteste’s Panuri program peer-reviewed scientific backing as the company pushes toward European regulatory review. - Panuri is being developed to detect pancreatic cancer earlier through a non-invasive urine test, a market where earlier diagnosis could affect survival and treatment timing.

What happened: - Urteste announced the publication of its first peer-reviewed scientific article on Panuri, an investigational in vitro diagnostic device for pancreatic cancer. - The paper, titled "Development and Analytical Evaluation of Urine-Based Test for Detection of Pancreatic Cancer," appeared in Diagnostics. - Urteste said the publication marks an important milestone for the company and supports the ongoing clinical development of Panuri. - Grzegorz Stefański, Urteste co-founder and CEO, said the paper documents the analytical work completed during development and that the company is continuing its international clinical study. - Stefański also said Urteste plans to present the latest Panuri progress at ADLM 2026 in Anaheim.

The details: - Panuri is a urine-based test being developed to support diagnosis of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. - The test measures disease-associated proteolytic activity in urine using proprietary synthetic peptides. - The analytical development showed 89% analytical sensitivity and 75% analytical specificity. - Urteste said the assay also demonstrated high analytical precision, including repeatability, within-laboratory precision and inter-laboratory reproducibility, with coefficients of variation below 10%. - The newly published article describes those results and the analytical validation performed during assay development. - Panuri is still investigational, has not received CE marking and is undergoing multicenter clinical performance evaluation across Europe under the IVDR. - The ongoing prospective study is enrolling patients undergoing diagnostic work-up for suspected pancreatic cancer. - The study is being run at 30 clinical sites in Poland, Italy and Hungary. - Urteste expects about 550 evaluable participants in the study. - The results are intended to support the European regulatory process for the Panuri IVD test under the In Vitro Diagnostic Medical Devices Regulation. - Urteste currently has 13 prototypes of diagnostic tests spanning cancers of the breast, brain, stomach, bile ducts, ovaries, bladder, endometrium, kidneys, colon, lungs, liver, pancreas and prostate. - Urteste said those cancers together account for nearly 70% of all cancer-related deaths worldwide. - The company’s technology detects biochemical changes linked to selected cancers by measuring enzyme activity in urine and tracking color changes in specific tests. - The article is available in Diagnostics (2026) at the published paper. - Members of Urteste’s management board will attend ADLM 2026, which runs July 26–30 in Anaheim, California. - Urteste said it plans to discuss the publication, the ongoing clinical study and potential strategic and commercial partnerships at the conference.

Between the lines: - The peer-reviewed paper may help Urteste build credibility with clinicians, regulators and potential partners as the company moves from analytical validation into broader clinical evidence generation. - The ADLM appearance suggests Urteste is using a major diagnostics conference to market the Panuri platform while the regulatory and clinical program continues.

What's next: - Urteste will keep running the multicenter European clinical study for Panuri. - The company will use ADLM 2026 to update the diagnostics community on Panuri progress and pursue partnership talks. - The next major catalyst appears to be clinical performance data that can support the European regulatory pathway.